All In Biotech

Free tool

FAERS Monitor: Tyruko

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761322 or its brand name (Tyruko, Natalizumab-Sztn). Reports on generic versions are filed under their own applications.

Reports

237

Serious

217

92% of reports

Hospitalization

28

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue73
  • mobility decreased53
  • balance disorder31
  • headache22
  • product substitution issue21
  • muscular weakness17
  • multiple sclerosis relapse16
  • cognitive disorder14
  • gait disturbance13
  • progressive multifocal leukoencephalopathy13
  • dizziness12
  • nausea12
  • urinary incontinence11
  • multiple sclerosis9
  • rash9

Reports by year received

View as table
YearReports
2024110
202592
202635

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
progressive multifocal leukoencephalopathySignal13140.182.61,657
mobility decreasedSignal5365.551.73,312
urinary incontinenceSignal1133.018.5310
product substitution issueSignal2132.421.5609
balance disorderSignal3131.822.9899
cognitive disorderSignal1426.616.0321
multiple sclerosis relapseSignal1620.712.9282
multiple sclerosisSignal916.78.8118
muscular weaknessSignal1713.38.4182
fatigueSignal738.36.9481
gait disturbanceSignal136.03.650
headacheSignal223.12.130
dizzinessSignal122.11.26
rash91.81.03
nausea121.30.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.